Abstract
Haloperidol is the best-known most worldwide used classic first-generation (typical) antipsychotic, commonly used for positive symptoms of schizophrenia. Besides oral and parenteral forms, a long-acting depot formulation as an injection every 4 weeks is also available. As a high-potency antipsychotic acting as D2 receptor antagonist, it tends to produce significant extrapyramidal side effects. The efficacy in treatment of psychoses was established in numerous randomized, double-blind, placebo-controlled and maintenance studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams C, Bergman H, Irving C. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD003082.
Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987;33(1):31–49.
Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev. 2006;19:CD004362.
Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen MR, Marwa ME, AlMounayer N. Haloperidol discontinuation for people with schizophrenia. Cochrane Database Syst Rev. 2019;4:CD011408.
Grange B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17:137–40.
Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs. 2016;30:27–39.
Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
Khushu A, Powney MJ. Haloperidol for long-term aggression in psychosis. Cochrane Database Syst Rev. 2016;11:CD009830. https://doi.org/10.1002/14651858.CD009830.pub2.
Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P. Persistence of haloperidol in human brain tissue. Am J Psychiatry. 1999;156:885–90.
Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435–56.
Lao KSJ, Wong AYS, Wong ICK, Besag FMC, Chang WC, Lee EHM, Chen EYH, Blais JE, Chan EW. Mortality risk associated with haloperidol use compared with other antipsychotics: an 11-year population-based propensity-score-matched cohort study. CNS Drugs. 2020;34:197–206.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063–71.
Leucht S, Cipriani A, Spineli L, Mavridis D, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.
Lopez-Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009;79:130–41.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.
Rasmussen SA, Rosebush PI, Mazurek MF. The relationship between early haloperidol response and associated extrapyramidal side effects. J Clin Psychopharmacol. 2017;37:8–12.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. Int Pharmacopsychiatry. 1982;17:238–46.
Schotte A, Janssen PF, Megens AA, Leysen JE. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993;631:191–202.
Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia. CNS Drugs. 2001;15:671–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Laux, G. (2022). Haloperidol in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_127
Download citation
DOI: https://doi.org/10.1007/978-3-030-62059-2_127
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62058-5
Online ISBN: 978-3-030-62059-2
eBook Packages: MedicineReference Module Medicine